Traduction de «translation of cas de systèmes » (Français → Anglais) :

nick translation

Translatory motion

disentailing assurance

Definition: Symptoms are presented by the patient as if they were due to a physical disorder of a system or organ that is largely or completely under autonomic innervation and control, i.e. the cardiovascular, gastrointestinal, respiratory and urogenital systems. The symptoms are usually of two types, neither of which indicates a physical disorder of the organ or system concerned. First, there are complaints based upon objective signs of autonomic arousal, such as palpitations, sweating, flushing, tremor, and expression of fear and distress about the possibility of a physical disorder. Second, there are subjective complaints of a nonspec ...[+++]ific or changing nature such as fleeting aches and pains, sensations of burning, heaviness, tightness, and feelings of being bloated or distended, which are referred by the patient to a specific organ or system. | Cardiac neurosis Da Costa's syndrome Gastric neurosis Neurocirculatory asthenia Psychogenic forms of:aerophagy | cough | diarrhoea | dyspepsia | dysuria | flatulence | hiccough | hyperventilation | increased frequency of micturition | irritable bowel syndrome | pylorospasm

nick translation

Definition: Any other disorders of sensation, function and behaviour, not due to physical disorders, which are not mediated through the autonomic nervous system, which are limited to specific systems or parts of the body, and which are closely associated in time with stressful events or problems. | Psychogenic:dysmenorrhoea | dysphagia, including globus hystericus | pruritus | torticollis | Teeth-grinding

Modifiers The following fourth-character subdivisions are for use with categories E10-E14: Code Title .0 With coma Diabetic:coma with or without ketoacidosis | hyperosmolar coma | hypoglycaemic coma | Hyperglycaemic coma NOS .1 With ketoacidosis Diabetic:acidosis | ketoacidosis | without mention of coma | .2+ With renal complications Diabetic nephropathy (N08.3*) Intracapillary glomerulonephrosis (N08.3*) Kimmelstiel-Wilson syndrome (N08.3*) .3+ With ophthalmic complications Diabetic:cataract (H28.0*) | retinopathy (H36.0*) | .4+ With neurological complications Diabetic:amyotrophy (G73.0*) | autonomic neuropathy (G99.0*) | mononeuropathy ...[+++] (G59.0*) | polyneuropathy (G63.2*) autonomic (G99.0*) | .5 With peripheral circulatory complications Diabetic:gangrene | peripheral angiopathy+ (I79.2*) | ulcer | .6 With other specified complications Diabetic arthropathy+ (M14.2*) Neuropathic diabetic arthropathy+ (M14.6*) .7 With multiple complications .8 With unspecified complications .9 Without complications | Diabetic:coma with or without ketoacidosis | hyperosmolar coma | hypoglycaemic coma | Hyperglycaemic coma NOS | Diabetic:acidosis | ketoacidosis | without mention of coma | Diabetic nephropathy (N08.3*) Intracapillary glomerulonephrosis (N08.3*) Kimmelstiel-Wilson syndrome (N08.3*) | Diabetic:cataract (H28.0*) | retinopathy (H36.0*) | Diabetic:amyotrophy (G73.0*) | autonomic neuropathy (G99.0*) | mononeuropathy (G59.0*) | polyneuropathy (G63.2*) autonomic (G99.0*) | Diabetic:gangrene | peripheral angiopathy+ (I79.2*) | ulcer | Diabetic arthropathy+ (M14.2*) Neuropathic diabetic arthropathy+ (M14.6*)

United Kingdom children's cancer study group central nervous system tumor staging system

Respiratory disease

[32] Translation services — Service requirements, document WI CSA07001, prepared by the Technical Committee CEN/BTTF 138.

Range of process issues relating to consumer assurance schemes identified by the European Economic and Social Committee:a) Scheme Governance Where does ultimate control of the scheme lie?b) Scheme Goals Are the goals clearly defined?c) Scheme scope Does the scheme address the "problem" as normally defined?d) Scheme standards or terms Do the standards set and monitored by the scheme express the goals? e) Impact assessment Is there credible assessment of the impact of the scheme on the goals?f) Independent review Is there any independent review of the scheme's operation?g) Cost-benefit analysis Is there any process to monitor and evaluate the costs of the scheme borne by suppliers, traders and consumers in comparison to the progress made to achieve the goals? ...[+++]h) Public claims Do the public claims by certified companies or suppliers match the goals, standards and outcomes of the scheme?

The Czech Republic, the Kingdom of Denmark, the Republic of Estonia, the Italian Republic, the Kingdom of the Netherlands and the Republic of Finland requested the Commission to set up the European Advanced Translational Research Infrastructure in Medicine as a European Research Infrastructure Consortium (EATRIS ERIC).

On 22 December 1975, the Commission concluded with the American company World Translation Center Inc (WTC) a first contract concerning the installation and development of an (English-French) machine translation software system called Systran (SYStem TRANSlation), created by that company in 1968.